Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Arrowhead Pharmaceuticals, Inc.

http://arrowheadpharma.com/

Latest From Arrowhead Pharmaceuticals, Inc.

Vir Advances HBV, Flu Programs While Focused On COVID-19

Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.

Infectious Diseases Business Strategies

Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs

The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.

Deals Business Strategies

Coronavirus Update: Fujifilm Drug Shows Promise, Arrowhead Halts Trial Screening, Novartis Unveils COVID-19 Measures

Flu drug produces encouraging results in Chinese trials, while Novartis CEO Vas Narasimhan shows his public health background with package of measures.

International Coronavirus COVID-19

Stockwatch: Is Alnylam’s Rare Disease Business Model Sustainable?

Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.

Platform Technologies Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Other Names / Subsidiaries
    • Ablaris Therapeutics, Inc.
    • Alvos Therapeutics, Inc. (formerly Mercator Therapeutics, Inc.)
    • Arrowhead Research Corporation
    • Calando Pharmaceuticals, Inc.
    • Unidym
UsernamePublicRestriction

Register